The Traderszone Network

11 September, 2021 by The TZ Newswire Staff Comments Off on 5 Leading Growth Stocks to Buy in 2021 and Beyond

5 Leading Growth Stocks to Buy in 2021 and Beyond

Investors who can identify “big picture” trends and have the patience to wait for those trends to take hold can be rewarded with great long-term returns. We often get caught up in the day-to-day headlines we see on the news, but it’s often a yearslong view that benefits investors the most.

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on Zoom Is Unlikely to Lose Too Much Growth Momentum. Here’s Why

Zoom Is Unlikely to Lose Too Much Growth Momentum. Here’s Why

Shares of videoconferencing darling Zoom Video Communications (NASDAQ: ZM) crashed after guidance for the second half of this year failed to impress investors. The stock is back near 52-week lows, and at nearly half the value it had last autumn when shareholder optimism was sky-high.

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on 3 Top E-Commerce Stocks to Buy Right Now

3 Top E-Commerce Stocks to Buy Right Now

E-commerce stocks are suffering from a perception problem. Coming out of the pandemic, some investors believe e-commerce will suffer as more shoppers clamor for the in-store experience. While this might be true in the short term, e-commerce is well-positioned for long-term growth.

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on 2 Stocks That Jumped Friday Despite a Terrible Market

2 Stocks That Jumped Friday Despite a Terrible Market

Investors came into Friday knowing that the week had been a bad one for the stock market, but they’d hoped that Wall Street would find a way to claw back some of the losses on Friday. Unfortunately, that wasn’t the case, as worries about the COVID-19 pandemic and the potential for continued political backlash weighed on investor sentiment.

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?

Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?

Pfizer (NYSE: PFE) recently reported positive results for its experimental drug abrocitinib in a late-stage study targeting eczema, an inflammatory skin disease also known as atopic dermatitis. The study featured a head-to-head comparison between Pfizer’s drug and Dupixent, which is marketed by Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN).

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on 3 Reasons to Buy Intel, and 1 Reason To Sell

3 Reasons to Buy Intel, and 1 Reason To Sell

Intel (NASDAQ: INTC) has been a lackluster investment over the past three years. The chipmaker’s stock has risen about 15%, but has trailed far behind the PHLX Semiconductor Index‘s gain of approximately 130%.

read more

11 September, 2021 by The TZ Newswire Staff Comments Off on 5 of the Safest Dividend Stocks Retirees Can Buy Right Now

5 of the Safest Dividend Stocks Retirees Can Buy Right Now

Though there are a lot of ways to make money in the stock market, few have proved more successful than investing in dividend stocks. A study from J.P. Morgan Asset Management, a subsidiary of JPMorgan Chase, showed that companies initiating and growing their payouts between 1972 and 2012 averaged an annual return of 9.5%.

read more